Key corporate developments are headlined by Kuaishou-W (01024), which has secured a strategic investment of RMB 1.4 billion from the National Artificial Intelligence Fund into its Beijing Keling subsidiary. Meanwhile, China Financial Development (03623) has announced plans to acquire a 45% stake in GNW Capital Limited, which would lift its total holding to 96%.

Xinyi Glass (00868) intends to spin off and separately list its automotive glass business on the Main Board of the Stock Exchange of Hong Kong. Minglue Technology-W (02718), through its subsidiary, is set to acquire an 11.33% equity interest in Wuhan Yeying. CSPC Pharmaceutical (01093) has initiated the first research center for the Phase I clinical trial of SYH2092 injection, targeting weight management in adults who are overweight or obese.

Nexchip Semiconductor (02249) proposes to inject its entire equity in Hefei Ruiyu Technology into Anhui Ruijing Semiconductor as a capital increase. Sino Biopharmaceutical (01177) has entered into an exclusive licensing agreement with Cipla for TQB2102. Shanghai Pharmaceuticals (02607) has received production approval for ruxolitinib phosphate tablets. Ocumension Therapeutics-B (01477) has completed the first patient enrollment in the Phase III clinical trial for OT-202.

Shandong Xinhua Pharmaceutical (00719) has passed the generic drug consistency evaluation for azithromycin tablets. True Health Medicine-B (02697) has signed a sales contract worth nearly RMB 100 million for its puncture surgery navigation and positioning system. China Technology Group (01725) will form a strategic partnership with Gaolian Digital Technology to establish a joint venture, capitalizing on advantages in precision manufacturing and intelligent terminals. Baidu Group-W (09888) has announced its dual primary listing on the Main Board of the Hong Kong Stock Exchange.

On the operational front, Ingdan Innovation (00400) posted interim results with a 111.1% year-on-year increase in attributable profit to RMB 279 million. Zhenli New Energy (03677) reported a 68.6% rise in attributable profit to RMB 372 million for the period, with power battery business revenue climbing 53.3% year-on-year. Horizon Robotics-W (09660) turned around to a net profit of RMB 3.784 billion in its interim results, with its share of the domestic ADAS market for self-owned brands surpassing 50% for the first time.

Lin Qingxuan (02657) delivered a net profit of RMB 256 million in its interim report, up 40.7% from a year earlier. Angelalign (06699) saw attributable profit grow 86.1% to USD 27.251 million. Zhiyuan Holdings (00990) recorded impressive interim numbers, with operating profit surging 139% and a clearer transformation roadmap. Jiufang Zhitou Holdings (09636) reported its 2026 interims, highlighting progress in its AI-powered omnichannel strategy and the development of a closed-loop investment advisory service.